New 3D ‘Mini-Brain’ Models Offer Promising Path for Multiple Sclerosis Drug Testing
Researchers have engineered innovative three-dimensional “mini-brains” designed to accelerate the development of much-needed therapies for multiple sclerosis (MS). Published in the journal Nature Neuroscience, the breakthrough provides scientists with a sophisticated human-relevant model to examine the destruction and regeneration of myelin—the protective sheath surrounding nerve fibers that is heavily impacted by the autoimmune condition.
The collaborative project was led by specialists from The Florey Institute of Neuroscience and Mental Health and Monash University, with contributions from institutions across Australia and New Zealand. Measuring roughly the size of a grain of rice, the tiny models were constructed using reprogrammed adult stem cells to simulate complex central nervous system environments. They represent one of only a small number of similar MS organoids developed globally.
Multiple sclerosis is an autoimmune disorder affecting nearly 3 million individuals worldwide. In healthy individuals, myelin acts as a vital insulating layer that enables electrical impulses to travel rapidly along the brain, spinal cord, and the rest of the body. In patients with MS, the immune system mistakenly attacks this protective barrier, triggering progressive nerve damage, neurological symptoms, and long-term disability. Currently, available pharmaceutical treatments can manage symptoms and slow down disease progression, but there are no approved therapies capable of directly repairing damaged myelin.
Associate Professor Samantha Barton, head of the Myelin in Health and Disease Group at The Florey, noted that the intricate cell model required more than six years of development. Traditional preclinical studies heavily rely on rodent models, yet treatments that appear successful in animal trials frequently fail when tested in humans. By introducing immune cells directly into the lab-grown organoids, the research team successfully simulated MS-like injury, opening new avenues to observe the natural mechanisms of remyelination.
“In addition to generating myelin, we have been able to introduce immune cells to trigger injury similar to MS,” Associate Professor Barton stated. “This gives us the unique opportunity to study the regenerative process of remyelination in the laboratory. This model can help researchers better understand what drives myelin damage and repair in MS and it also gives us a new platform to screen drugs that protect or restore myelin.”
Dr. Shwathy Ramesan, a postdoctoral fellow at The Florey and first author of the study, emphasized that observing potential drug candidates work on human cells in near real time represents a major turning point for the scientific community. The platform is expected to give investigators an unprecedented window into human myelin biology, allowing laboratories worldwide to refine experimental treatments more efficiently.
Co-senior author Associate Professor David Gonsalvez of Monash University highlighted the potential for discovering therapeutics that actively stimulate natural repair mechanisms. While the human body possesses some inherent ability to restore central nervous system insulation, these native processes are typically limited. Researchers hope to utilize the new spheroids to identify compounds that can boost these repair pathways.
While further investigations and clinical trials are required before any new treatments reach patients, the development of these advanced organoids marks an important step toward finding effective interventions that could eventually halt or prevent the progression of multiple sclerosis.
Source: Medical Xpress
